Cancer immunotherapy: are we there yet?
- PMID: 24326015
- PMCID: PMC4176488
- DOI: 10.1186/2162-3619-2-33
Cancer immunotherapy: are we there yet?
Abstract
The immune system is the built-in host defense mechanism against infectious agents as well as cancer. Protective immunity against cancer was convincingly demonstrated in the 1940s with syngeneic animal models (JNCI 18:769-778, 1976; Cancer Immun 1:6, 2001). Since then, the last century's dream has been to effectively prevent and cure cancers by immunological means. This dream has slowly but surely become a reality (Nature 480:480-489, 2011). The successful examples of immunoprophylaxis and therapy against cancers include: (i) targeted therapy using monoclonal antibodies (Nat Rev Cancer 12:278-287, 2012); (ii) allogeneic hematopoietic stem cell transplantion to elicit graft-versus-cancer effect against a variety of hematopoietic malignancies (Blood 112:4371-4383, 2008); (iii) vaccination for preventing cancers with clear viral etiology such as hepatocellular carcinoma and cervical cancer (Cancer J Clin 57:7-28, 2007; NEJM 336:1855-1859, 1997); (iv) T cell checkpoint blockade against inhibitory pathways including targeting CTLA-4 and PD-1 inhibitory molecules for the treatment of melanoma and other solid tumors (NEJM 363:711-723, 2010; NEJM 366:2443-2454, 2012; NEJM 369:122-133, 2013; NEJM 366:2455-2465, 2012); (v) antigen-pulsed autologous dendritic cell vaccination against prostate cancer (NEJM 363:411-422, 2010); and (vi) the transfer of T cells including those genetically engineered with chimeric antigen receptors allowing targeting of B cell neoplasms (NEJM 365:725-733, 2011; NEJM 368:1509-1518, 2013; Blood 118:4817-4828, 2013; Sci Transl Med 5:177ra138, 2013).This article provides an overview on the exciting and expanding immunological arsenals against cancer, and discusses critical remaining unanswered questions of cancer immunology. The inherent specificity and memory of the adaptive immune response towards cancer will undoubtedly propel cancer immunotherapy to the forefront of cancer treatment in the immediate near future. Study of the fundamental mechanisms of the immune evasion of cancer shall also advance the field of immunology towards the development of effective immunotherapeutics against a wide spectrum of human diseases.
Figures
Similar articles
-
Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.Int Immunopharmacol. 2003 Aug;3(8):1121-43. doi: 10.1016/S1567-5769(03)00014-6. Int Immunopharmacol. 2003. PMID: 12860168 Review.
-
Active Immunotherapy of Cancer.Immunol Invest. 2015;44(8):817-36. doi: 10.3109/08820139.2015.1096684. Immunol Invest. 2015. PMID: 26575466 Review.
-
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.Curr Med Chem. 2018;25(11):1327-1339. doi: 10.2174/0929867324666170407125017. Curr Med Chem. 2018. PMID: 28403786 Review.
-
Immune Checkpoint Blockade in Breast Cancer Therapy.Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18. Adv Exp Med Biol. 2017. PMID: 29282694 Review.
-
The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.Front Immunol. 2021 Mar 5;12:634435. doi: 10.3389/fimmu.2021.634435. eCollection 2021. Front Immunol. 2021. PMID: 33746972 Free PMC article. Review.
Cited by
-
Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis.Medicine (Baltimore). 2020 Jul 10;99(28):e21273. doi: 10.1097/MD.0000000000021273. Medicine (Baltimore). 2020. PMID: 32664183 Free PMC article.
-
Immune checkpoint blockade therapy for bladder cancer treatment.Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S98-S105. doi: 10.4111/icu.2016.57.S1.S98. Epub 2016 May 26. Investig Clin Urol. 2016. PMID: 27326412 Free PMC article. Review.
-
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018. Front Immunol. 2018. PMID: 29497427 Free PMC article. Review.
-
Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy.Sci Rep. 2017 Feb 16;7:42855. doi: 10.1038/srep42855. Sci Rep. 2017. PMID: 28205621 Free PMC article.
-
Tumor Cell Death via Apoptosis and Improvement of Activated Lymphocyte Cytokine Secretion by Extracts from Euphorbia Hebecarpa and Euphorbia Petiolata.Asian Pac J Cancer Prev. 2019 Jul 1;20(7):1979-1988. doi: 10.31557/APJCP.2019.20.7.1979. Asian Pac J Cancer Prev. 2019. PMID: 31350954 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources